Evidence map›Paper›PMID 30110052›Full record

ReviewArquivos brasileiros de cardiologia2018

Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk.

Paulo Eduardo Ballvé Behr, Emilio Hideyuki Moriguchi, Iran Castro, Luiz Carlos Bodanese, Oscar Pereira Dutra, Paulo Ernesto Leães, Pedro Pimentel Filho

Full text readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Arquivos brasileiros de cardiologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. The number needed to benefit: estimating the value of predictive analytics in healthcare.Journal of the American Medical Informatics Association : JAMIA · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Paulo Eduardo Ballvé BehrHospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS - Brazil.
Emilio Hideyuki MoriguchiFaculdade de Medicina - Universidade Federal do Rio Grande do Sul, Porto Alegre, RS - Brazil.
Iran CastroInstituto de Cardiologia / Fundação Universitária de Cardiologia, Porto Alegre, RS - Brazil.
Luiz Carlos BodaneseHospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS - Brazil.
Oscar Pereira DutraInstituto de Cardiologia / Fundação Universitária de Cardiologia, Porto Alegre, RS - Brazil.
Paulo Ernesto LeãesIrmandade Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS - Brazil.
Pedro Pimentel FilhoHospital Nossa Senhora da Conceição, Porto Alegre, RS - Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

PCSK9 InhibitorsAntibodies, MonoclonalCardiovascular DiseasesCholesterol, LDLCost-Benefit AnalysisHumansProprotein Convertase 9Risk FactorsAntibodies, MonoclonalCholesterol, LDLPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9

Identifiers

PMID30110052
PMCPMC6078356

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.